PBF-680 Market Insights

Key Factors Driving PBF-680 Growth

1) Large asthma and COPD patient pool creates significant market opportunity

Asthma and COPD remain massive global markets with persistent unmet need:

• According to the WHO, asthma affects nearly 262 million people globally

• COPD affects approximately ~390 million people worldwide

• COPD caused 3.5 million deaths globally in 2021

Despite widespread use of inhaled corticosteroids, LABAs, LAMAs, and biologics, a large subset of patients still experience poor symptom control or exacerbations. An oral therapy like PBF-680 could target patients inadequately controlled on standard inhaled therapies.

2) Novel mechanism of action (A1 receptor antagonism) offers differentiation

PBF-680 targets the adenosine A1 receptor, a relatively underexplored pathway in respiratory disease.

Adenosine plays a major role in:

• Bronchoconstriction

• Airway hyperresponsiveness

• Inflammation

• Eosinophilic activity

Unlike currently approved respiratory biologics that target IL-4, IL-5, or IgE pathways, PBF-680 offers a differentiated oral mechanism that could potentially be used earlier in the treatment pathway.

3) Positive Phase II asthma efficacy data

In September 2020, Palobiofarma announced positive Phase II data showing:

• Statistically significant improvement in trough FEV1 vs placebo

• Significant improvement in FEV1 AUC

• Improvement in Asthma Control Questionnaire (ACQ) scores

• Significant reduction in eosinophil counts

Patients received 10 mg oral PBF-680 for 14 days, and notably no serious adverse events were reported. These results were among the biggest validation points for the drug’s commercial potential.

 

4) Proof-of-concept data showed reduction in late asthmatic response

In another Phase IIa proof-of-concept study, PBF-680:

• Reduced late allergic response (LAR)

• Reduced early allergic response (EAR)

• Lowered FeNO levels

• Reduced blood eosinophils

These findings suggest PBF-680 may have both bronchodilatory and anti-inflammatory benefits—important for long-term asthma management.

5) Expansion into COPD broadens total addressable market

Palobiofarma initiated a Phase IIa COPD study (NCT05262218) evaluating PBF-680 in approximately 114 moderate-to-severe COPD patients on top of standard therapy.

If successful, COPD could represent a much larger commercial opportunity than asthma because of higher prevalence, chronic use potential, and limited innovation in oral respiratory therapies.

 

PBF-680 Recent Developments

In April 2024, Palobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe COPD patients. The trial has recruited 104 patients in 12 hospitals in Spain. The primary endpoint of the study is the change from baseline in blood eosinophils, which correlates with the risk of exacerbation in this population. 

“PBF-680 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of PBF-680 for potential indication like Asthma and Chronic obstructive pulmonary disease in the 7MM. A detailed picture of PBF-680’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the PBF-680 for potential indications. The PBF-680 market report provides insights about PBF-680’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current PBF-680 performance, future market assessments inclusive of the PBF-680 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of PBF-680 sales forecasts, along with factors driving its market.

 

PBF-680 Drug Summary

PBF-680 is an investigational, orally administered small-molecule selective antagonist of the Adenosine A1 receptor, developed by Palobiofarma S.L. for the treatment of respiratory diseases, particularly Chronic Obstructive Pulmonary Disease and asthma. By blocking adenosine A1 receptor signaling in the lungs, PBF-680 is designed to reduce bronchoconstriction, airway inflammation, and mucus production—mechanisms that contribute to airflow limitation in chronic respiratory disorders. Early clinical studies have demonstrated bronchodilatory effects and a favorable safety profile, supporting its potential as a novel non-steroidal therapeutic option for patients with inadequately controlled respiratory disease. The drug remains in clinical development as researchers continue to evaluate its efficacy and differentiation within the competitive COPD treatment landscape. The report provides PBF-680’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the PBF-680 Market Report

The report provides insights into:

• A comprehensive product overview including the PBF-680 MoA, description, dosage and administration, research and development activities in potential indication like Asthma and Chronic obstructive pulmonary disease.

• Elaborated details on PBF-680 regulatory milestones and other development activities have been provided in PBF-680 market report.

• The report also highlights PBF-680‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.

• The PBF-680 market report also covers the patents information, generic entry and impact on cost cut.

• The PBF-680 market report contains current and forecasted PBF-680 sales for potential indications till 2034.

• Comprehensive coverage of the late-stage emerging therapies for respective indications.

• The PBF-680 market report also features the SWOT analysis with analyst views for PBF-680 in potential indications.

 

Methodology

The PBF-680 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

PBF-680 Analytical Perspective by DelveInsight

• In-depth PBF-680 Market Assessment

This PBF-680 sales market forecast report provides a detailed market assessment of PBF-680 for potential indication like Asthma and Chronic obstructive pulmonary disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted PBF-680 sales data uptil 2034.

• PBF-680 Clinical Assessment

The PBF-680 market report provides the clinical trials information of PBF-680 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

PBF-680 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

PBF-680 Market Potential & Revenue Forecast

• Projected market size for the PBF-680 and its key indications

• Estimated PBF-680 sales potential (PBF-680 peak sales forecasts)

• PBF-680 Pricing strategies and reimbursement landscape

PBF-680 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)

• PBF-680 Market positioning compared to existing treatments

• PBF-680 Strengths & weaknesses relative to competitors

PBF-680 Regulatory & Commercial Milestones

• PBF-680 Key regulatory approvals & expected launch timelines

• Commercial partnerships, licensing deals, and M&A activity

PBF-680 Clinical Differentiation

• PBF-680 Efficacy & safety advantages over existing drugs

• PBF-680 Unique selling points

 

PBF-680 Market Report Highlights

• In the coming years, the PBF-680 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.

• The PBF-680 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PBF-680’s dominance.

• Other emerging products for Asthma and Chronic obstructive pulmonary disease are expected to give tough market competition to PBF-680 and launch of late-stage emerging therapies in the near future will significantly impact the market.

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PBF-680 in potential indications.

• Analyse PBF-680 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.

• Our in-depth analysis of the forecasted PBF-680 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of PBF-680 in potential indications.

 

Key Questions

• What is the class of therapy, route of administration and mechanism of action of PBF-680? How strong is PBF-680’s clinical and commercial performance?

• What is PBF-680’s clinical trial status in each individual indications such as Asthma and Chronic obstructive pulmonary disease and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PBF-680 Manufacturers?

• What are the key designations that have been granted to PBF-680 for potential indications? How are they going to impact PBF-680’s penetration in various geographies?

• What is the current and forecasted PBF-680 market scenario for potential indications? What are the key assumptions behind the forecast?

• What are the current and forecasted sales of PBF-680 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 

• What are the other emerging products available and how are these giving competition to PBF-680 for potential indications?

• Which are the late-stage emerging therapies under development for the treatment of potential indications?

• How cost-effective is PBF-680? What is the duration of therapy and what are the geographical variations in cost per patient?